GlassScriptPhysician profile
Samantha S Lang
NPI 1447584719
$2,051.07
in general payments reported to CMS, 2019-2025
29 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $57.46 · 2023: $773 · 2024: $877 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,770 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,769.61 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $450.22 | 2023-2024 | Reblozyl |
| Gilead Sciences, INC. | $273.07 | 2023-2024 | Trodelvy |
| Incyte Corporation | $232.46 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $135.39 | 2024 | Vtama |
| Celgene Corporation | $121.04 | 2024 | Reblozyl, Pomalyst |
| Tempus Ai, INC | $75.05 | 2024 | |
| Novartis Pharmaceuticals Corporation | $74.41 | 2024 | |
| Kite Pharma, INC. | $63.05 | 2023 | |
| Genentech USA, INC. | $59.02 | 2022-2024 | Ocrevus, Ocrevus Zunovo |
| Daiichi Sankyo INC. | $54.58 | 2023-2024 | Enhertu |
| Amgen INC. | $50.53 | 2023 | Nplate, Xgeva, Blincyto |
| Merck Sharp & Dohme LLC | $49.05 | 2023-2024 | Keytruda, Lynparza |
| Leo Pharma INC. | $37.60 | 2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $36.18 | 2025 | Dupixent |
| Sobi, INC | $34.12 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $29.78 | 2022-2024 | Onivyde, Somatuline Depot |
| Novo Nordisk INC | $28.46 | 2022 | |
| Biofrontera INC. | $28.00 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $27.41 | 2024 | |
| Astellas Pharma US INC | $24.44 | 2024 | Padcev |
| Genzyme Corporation | $23.80 | 2024 | |
| Lilly USA, LLC | $23.15 | 2024 | Olumiant |
| Emd Serono, INC. | $19.26 | 2024 | |
| Seagen INC. | $19.20 | 2023 | Padcev |
| Takeda Pharmaceuticals U.S.A., INC. | $19.00 | 2024 | Entyvio |
| Ucb, INC. | $18.20 | 2025 | Bimzelx |
| Tolmar, INC. | $15.92 | 2024 | |
| Genmab U.S., INC. | $15.40 | 2023 | Epkinly |
| Argenx US, INC. | $13.28 | 2023 | Vyvgart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Lang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.